Radioactive injection targets Hard-to-Treat cancers in early trial
NCT ID NCT07274852
First seen Jan 08, 2026 · Last updated May 20, 2026 · Updated 19 times
Summary
This early-phase study tests a new radioactive drug (lutetium [177Lu]-BL-ARC001) in 22 adults with advanced lung, breast, head/neck, or other solid tumors that have not responded to standard treatments. The main goals are to check safety, find the best dose, and see if the drug shrinks tumors. Participants receive the drug by injection and are closely monitored for side effects and tumor response.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
West China Hospital of Sichuan University
RECRUITINGChengdu, Sichuan, China
Contact
Contact
Contact
Conditions
Explore the condition pages connected to this study.